Biophage Pharma Announces Breaktrough in Live Bacteria Quantification With Nanosensor Technology.MONTREAL -- New Technology can detect presence of 5-10 Bacteria in a Liquid Sample Biophage Pharma Inc. (TSX-V: BUG), a biopharmaceutical company engaged in the development of new therapeutics and clinical diagnostics based on its leading expertise in immunology immunology, branch of medicine that studies the response of organisms to foreign substances, e.g., viruses, bacteria, and bacterial toxins (see immunity). Immunologists study the tissues and organs of the immune system (bone marrow, spleen, tonsils, thymus, lymphatic and phage therapy Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections. Bacteriophages, or "phages" are viruses that invade only bacterial cells and, in the case of lytic , announced today that it has reached a significant milestone in the detection and quantification of bacteria. The continued development of the Nanosensor has enabled Biophage to detect 5 to 10 bacteria in 1 ml of liquid sample.By allowing the detection of very small number of bacteria in a short period of time, this Nonosensor technology will be a valuable tool for environmental monitoring and biodefense. "I am very pleased to announce that our recent results represent a breakthrough in the quantification of bacteria in a liquid sample," stated Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage Pharma Inc. "Based on innovations in Impedance Spectroscopy spectroscopy Branch of analysis devoted to identifying elements and compounds and elucidating atomic and molecular structure by measuring the radiant energy absorbed or emitted by a substance at characteristic wavelengths of the electromagnetic spectrum (including gamma ray, and Nanotechnology, our platform consists of a simple, label-free technique that requires very little sample manipulation. This technology can also be used to study cell toxicity and for high throughput screening," pursued Dr. Mandeville. The technology is being co-developed by Biophage and the Biotech Research Institute - CNRC CNRC Conseil National de Recherche Canada CNRC Commander Navy Recruiting Command CNRC Charles County Nursing and Rehabilitation Center (Maryland) (BRI See ISDN. BRI - Basic Rate Interface ) of Quebec. "In the spirit of true industrial partnership, this innovative program is a true success story between Biophage and BRI environment sector" added Dr Mandeville "Since its inception, the scientific results and the performance of this Biosensor A device that detects and analyzes body movement, temperature or fluids and turns it into an electronic signal. See lab on a chip and data glove. Biosensor led to the application for a provisional US patent. Several presentations were made to potential partners who will play a key role in the development of prototypes for this project," concluded Dr. Mandeville. About Biophage Pharma Inc. Biophage Pharma Inc. is a Canadian biopharmaceutical company developing new therapeutic and diagnostic products using phage-based technology. Founded in 1995, Biophage is located at the Biotechnology Research Institute in Montreal and employs 15 people, including a team of 13 researchers. Through an active research and development program, as well as in-licensing and collaboration agreements, Biophage is building a portfolio of promising new therapeutics collaboration agreements, Biophage is building a portfolio of promising new therapeutics (www.biophage.com). Biophage Pharma Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:BUG) |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion